RB
Recourse Biologics develops precision oncology therapeutics, including its lead first‑in‑class immunotherapy RB101 that enhances killer‑cell persistence, memory and cytotoxicity without systemic toxicity. The company also advances a pipeline of novel antibody‑drug conjugates and bispecific antibodies that target tumor‑selective antigens and redirect cytotoxic lymphocytes, monetizing through partnerships and eventual product sales.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Recourse Biologics develops precision immunotherapeutics for oncology, focusing on enhancing anti-tumor immune responses. Their lead molecule, RB101, is a first-in-class agent designed to improve killer cell persistence and cytotoxicity without systemic exhaustion. The company also utilizes a bispecific antibody platform to target novel tumor-selective antigens and redirect cytotoxic lymphocytes.